



04-19-01

0300

0400

3204/2 (4162.3)  
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of M. South et al.

Serial No. 09/717,051

Filed November 20, 2000

Confirmation No. 2191

For SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL URACILS USEFUL  
FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE

April 18, 2001

TO THE COMMISSIONER OF PATENTS AND TRADEMARKS,

SIR:

INFORMATION DISCLOSURE STATEMENT

In accordance with 37 C.F.R. 1.97 and 1.98 and MPEP 609, and  
in compliance with the duty of disclosure set forth in 37 C.F.R.  
1.56, applicants submit copies of the references listed on  
the attached PTO/SB/08A for consideration by the Patent and  
Trademark Office in the above-entitled application and to be made  
of record therein.


Respectfully submitted,

*Kathryn J. Doty*

Kathryn J. Doty, Reg. No. 40,593  
SENNIGER, POWERS, LEAVITT & ROEDEL  
One Metropolitan Square, 16th Floor  
St. Louis, Missouri 63102  
(314) 231-5400

KJD/rle

Express Mail Label No. EL757703544US


PTO/SB/08A  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary) 		<b>Complete if Known</b>	
		Application Number	09/717,051
		Filing Date	11-20-2000
		Confirmation Number	2191
		First Named Inventor	M. South et al.
		Group Art Unit	TBA
		Examiner Name	TBA
Sheet 1	of 2	Attorney Docket No.	3204/2 (4162.3)

U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY		
		Number	Kind Code <sup>2</sup> (if known)				
	1	5,656,645		Tamura et al.	08-12-1997		
	2	5,658,930		Tamura et al.	08-19-1997		
	3	6,011,158		Tamura et al.	01-4-2000		
FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T <sup>6</sup>
		Office	Number <sup>4</sup>	Kind Code <sup>2</sup> (if known)			
	4	WO	96/18644	A1	Corvas International Inc.	06-20-1996	x
	5	WO	97/46207	A2	Corvas International Inc.	12-11-1997	x
	6	WO	99/26926	A1	3-Dimensional Pharmaceuticals, Inc.	06-03-1999	x
	7	WO	00/69833	A1	Monsanto Company	11-23-2000	x
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.					T <sup>6</sup>
	8	MAJERUS, et al. "Anticoagulant, Thrombolytic, and Antiplatelet Drugs." Goodman & Gilman's The Pharmacological Basis of Therapeutics, Ninth Edition, 1996, pp. 1341-1359, McGraw-Hill, New York.					x
Examiner Signature				Date Considered			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)  		<b>Complete if Known</b>	
		Application Number	09/717,051
		Filing Date	11-20-2000
		Confirmation Number	2191
		First Named Inventor	M. South et al.
		Group Art Unit	TBA
		Examiner Name	TBA
Sheet 2	of 2	Attorney Docket No.	3204/2 (4162.3)

	9	HANDIN, R., "Bleeding and Thrombosis." Harrison's Principles of Internal Medicine, 12th Edition, 1991, pp. 348-353, McGraw-Hill, Inc., New York.	x
--	---	--	---

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231.  
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.